(REGN) Regeneron Pharmaceuticals - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 80.543m USD | Total Return: 40% in 12m
Eye Disease, Asthma, Cancer, Arthritis
Total Rating 59
Safety 94
Buy Signal 0.59
Biotechnology
Industry Rotation: +6.6
Industry Rotation: +6.6
Market Cap:
80.5B
Avg Turnover: 427M USD
Avg Turnover: 427M USD
ATR:
2.60%
Peers RS (IBD): 38.3
Peers RS (IBD): 38.3
Risk 5d forecast
Volatility39.8%
Rel. Tail Risk-4.37%
Reward TTM
Sharpe Ratio0.87
Alpha11.80
Character TTM
Beta0.641
Beta Downside0.563
Drawdowns 3y
Max DD59.69%
CAGR/Max DD-0.03
EPS (Earnings per Share)
EPS CAGR: -45.13%
EPS Trend: -39.0%
EPS Trend: -39.0%
Last SUE: -4.00
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 7.47%
Rev. Trend: 77.4%
Rev. Trend: 77.4%
Last SUE: 0.52
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: REGN Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company that develops and commercializes medicines for various diseases.
The companys product portfolio includes treatments for eye conditions, inflammatory diseases, cardiovascular issues, and cancer. Biotechnology companies typically invest heavily in research and development, with a long product development cycle.
REGN has strategic collaborations with other pharmaceutical companies, including Bayer and Alnylam Pharmaceuticals, for drug development and commercialization. These partnerships are common in the pharmaceutical sector to share development costs and expand market reach.
For more detailed financial analysis, ValueRay offers comprehensive insights.
- EYLEA sales growth drives revenue stability
- Dupixent expansion boosts immunology portfolio
- Pipeline success critical for future growth
- Regulatory approvals impact drug commercialization
- Competition from biosimilars pressures EYLEA market share
Piotroski VR‑10 (Strict)
7.0
| Net Income: 4.50b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 0.53 > 1.0 |
| NWC/Revenue: 95.19% < 20% (prev 103.6%; Δ -8.43% < -1%) |
| CFO/TA 0.12 > 3% & CFO 4.98b > Net Income 4.50b |
| Net Debt (-5.90b) to EBITDA (5.82b): -1.01 < 3 |
| Current Ratio: 4.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (107.5m) vs 12m ago -5.54% < -2% |
| Gross Margin: 85.35% > 18% (prev 0.86%; Δ 8.45k% > 0.5%) |
| Asset Turnover: 36.63% > 50% (prev 37.61%; Δ -0.98% > 0%) |
| Interest Coverage Ratio: 120.4 > 6 (EBITDA TTM 5.82b / Interest Expense TTM 43.8m) |
Altman Z''
10.00
| A: 0.34 (Total Current Assets 18.02b - Total Current Liabilities 4.37b) / Total Assets 40.56b |
| B: 0.88 (Retained Earnings 35.80b / Total Assets 40.56b) |
| C: 0.13 (EBIT TTM 5.27b / Avg Total Assets 39.16b) |
| D: 3.86 (Book Value of Equity 35.87b / Total Liabilities 9.30b) |
| Altman-Z'' Score: 10.04 = AAA |
Beneish M
-3.02
| DSRI: 0.92 (Receivables 5.74b/6.21b, Revenue 14.34b/14.20b) |
| GMI: 1.01 (GM 85.35% / 86.13%) |
| AQI: 1.12 (AQ_t 0.43 / AQ_t-1 0.38) |
| SGI: 1.01 (Revenue 14.34b / 14.20b) |
| TATA: -0.01 (NI 4.50b - CFO 4.98b) / TA 40.56b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of REGN shares?
As of April 09, 2026, the stock is trading at USD 775.53 with a total of 567,823 shares traded.
Over the past week, the price has changed by -0.22%, over one month by -0.78%, over three months by -3.06% and over the past year by +40.04%.
Over the past week, the price has changed by -0.22%, over one month by -0.78%, over three months by -3.06% and over the past year by +40.04%.
Is REGN a buy, sell or hold?
Regeneron Pharmaceuticals has received a consensus analysts rating of 4.28.
Therefore, it is recommended to buy REGN.
- StrongBuy: 14
- Buy: 5
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the REGN price?
| Analysts Target Price | 872.7 | 12.5% |
Regeneron Pharmaceuticals (REGN) - Fundamental Data Overview
as of 04 April 2026
P/E Trailing = 18.3844 P/E Forward = 18.0505
P/S = 5.6155
P/B = 2.6289
P/EG = 1.6562
Revenue TTM = 14.34b USD
EBIT TTM = 5.27b USD
EBITDA TTM = 5.82b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = 37.8m USD (from shortTermDebt, last quarter)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.90b USD (recalculated: Debt 2.71b - CCE 8.61b)
Enterprise Value = 74.64b USD (80.54b + Debt 2.71b - CCE 8.61b)
Interest Coverage Ratio = 120.4 (Ebit TTM 5.27b / Interest Expense TTM 43.8m)
EV/FCF = 18.29x (Enterprise Value 74.64b / FCF TTM 4.08b)
FCF Yield = 5.47% (FCF TTM 4.08b / Enterprise Value 74.64b)
FCF Margin = 28.45% (FCF TTM 4.08b / Revenue TTM 14.34b)
Net Margin = 31.41% (Net Income TTM 4.50b / Revenue TTM 14.34b)
Gross Margin = 85.35% ((Revenue TTM 14.34b - Cost of Revenue TTM 2.10b) / Revenue TTM)
Gross Margin QoQ = 84.95% (prev 86.11%)
Tobins Q-Ratio = 1.84 (Enterprise Value 74.64b / Total Assets 40.56b)
Interest Expense / Debt = 0.45% (Interest Expense 12.2m / Debt 2.71b)
Taxrate = 19.08% (199.1m / 1.04b)
NOPAT = 4.27b (EBIT 5.27b * (1 - 19.08%))
Current Ratio = 4.13 (Total Current Assets 18.02b / Total Current Liabilities 4.37b)
Debt / Equity = 0.09 (Debt 2.71b / totalStockholderEquity, last quarter 31.26b)
Debt / EBITDA = -1.01 (Net Debt -5.90b / EBITDA 5.82b)
Debt / FCF = -1.45 (Net Debt -5.90b / FCF TTM 4.08b)
Total Stockholder Equity = 30.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.50% (Net Income 4.50b / Total Assets 40.56b)
RoE = 14.83% (Net Income TTM 4.50b / Total Stockholder Equity 30.39b)
RoCE = 16.29% (EBIT 5.27b / Capital Employed (Equity 30.39b + L.T.Debt 1.99b))
RoIC = 13.19% (NOPAT 4.27b / Invested Capital 32.37b)
WACC = 7.98% (E(80.54b)/V(83.25b) * Re(8.24%) + D(2.71b)/V(83.25b) * Rd(0.45%) * (1-Tc(0.19)))
Discount Rate = 8.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -2.81%
[DCF] Terminal Value 77.04% ; FCFF base≈3.89b ; Y1≈3.53b ; Y5≈3.08b
[DCF] Fair Price = 598.4 (EV 56.28b - Net Debt -5.90b = Equity 62.18b / Shares 103.9m; r=7.98% [WACC]; 5y FCF grow -11.54% → 3.0% )
EPS Correlation: -39.05 | EPS CAGR: -45.13% | SUE: -4.0 | # QB: 0
Revenue Correlation: 77.36 | Revenue CAGR: 7.47% | SUE: 0.52 | # QB: 0
EPS next Quarter (2026-06-30): EPS=10.67 | Chg7d=-0.039 | Chg30d=-0.001 | Revisions Net=-1 | Analysts=23
EPS current Year (2026-12-31): EPS=44.88 | Chg7d=+0.101 | Chg30d=+0.192 | Revisions Net=-2 | Growth EPS=+1.3% | Growth Revenue=+9.3%
EPS next Year (2027-12-31): EPS=47.58 | Chg7d=+0.676 | Chg30d=+0.676 | Revisions Net=+1 | Growth EPS=+21.3% | Growth Revenue=+10.3%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.8% (Discount Rate 8.2% - Earnings Yield 5.4%)
[Growth] Growth Spread = +0.9% (Analyst 3.7% - Implied 2.8%)
External Resources